The library consists of specifically designed molecules targeting key enzymes and processes involved in both cancer and viral diseases. ViroStatics will identify and develop candidate compounds with activity against HIV, hepatitis C, and other viruses using the company’s proprietary screening methodologies. Specific terms of the license agreement were not announced.
Franco Lori, president and CEO of ViroStatics, said: “ViroStatics is extremely honored to partner with professors Botta, Schenone, and Maga to acquire this impressive library of compounds with potential applications in the treatment of cancer, HIV/AIDS and other chronic infections.
“Using our proprietary methodologies for screening these agents, ViroStatics plans to quickly begin to identify candidate compounds to move into preclinical development.”